ストックスクリーナーアプリを入手
1,062.19
3.38%
34.68
アフターアワーズ：
1063.50
1.31
+0.12%
前日終値:
$1,027.51
開ける：
$1032.55
24時間の取引高:
4.64M
Relative Volume:
1.23
時価総額：
$950.68B
収益：
$59.42B
当期純損益:
$18.41B
株価収益率:
52.53
EPS:
20.2197
ネットキャッシュフロー:
$6.44B
1週間 パフォーマンス:
+6.48%
1か月 パフォーマンス:
+3.60%
6か月 パフォーマンス:
+29.64%
1年 パフォーマンス:
+34.60%
1日の値動き範囲:
$1,032.55
$1,065.00
1週間の範囲:
$977.12
$1,065.00
52週間の値動き範囲:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
LLY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,062.19 | 919.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
214.17 | 509.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.45 | 394.69B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.19 | 254.37B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.26 | 248.95B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly (LLY): Revisiting Valuation After a Powerful Multi‑Month Share Price Rally - simplywall.st
Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.4%Time to Buy? - MarketBeat
Top 20 by Trading Value | Accelerated Commercialization of FSD Boosts Tesla Over 3% to New Yearly High; Faster Approval Process for Weight-Loss Drugs Lifts Eli Lilly and Co Over 3%, Market Cap Breaks $1 Trillion Mark Again; NVIDIA Launches Next-Gen - 富途牛牛
Eli Lilly Stock (LLY) After Hours Today: What to Know Before the Market Opens Tuesday, Dec. 16, 2025 - ts2.tech
Eli Lilly & Co. stock outperforms competitors on strong trading day - MSN
2 Predictions for Eli Lilly in 2026 - AOL.com
Bank of America Says Market Isn’t Pricing in Eli Lilly’s (LLY) Weight-Loss Drug Dominance - TipRanks
Why Eli Lilly (LLY) Stock Is Trading Up Today - Finviz
Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says - Benzinga
Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says - marketscreener.com
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025 - ts2.tech
Eli Lilly (LLY): B of A Securities Lowers Price Target Despite Buy Rating | LLY Stock News - GuruFocus
Lilly Building $6B Huntsville Pharma Plant - Connect CRE
V. M. Manning & CO. Inc. Invests $875,000 in Eli Lilly and Company $LLY - MarketBeat
Bank of America Has Lowered Expectations for Eli Lilly and Company (NYSE:LLY) Stock Price - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Julie Johnson - MarketBeat
Eli Lilly price target raised to $1,145 from $951 at Goldman Sachs - TipRanks
Eli Lilly and Company $LLY Shares Purchased by NWF Advisory Services Inc. - MarketBeat
Silicon Valley Capital Partners Boosts Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by SevenBridge Financial Group LLC - MarketBeat
Orion Porfolio Solutions LLC Has $39.62 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly & Co: Strategic Initiatives and Promising Market Opportunities Drive Buy Rating - TipRanks
Thrivent Financial for Lutherans Acquires 52,783 Shares of Eli Lilly and Company $LLY - MarketBeat
MASTERINVEST Kapitalanlage GmbH Acquires New Holdings in Eli Lilly and Company $LLY - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Trims Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly just delivered fantastic news to investors - MSN
Eli Lilly Just Delivered Fantastic News to Investors - Finviz
Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) (NYSE:LLY) - Seeking Alpha
Cim Investment Management Inc. Has $3.12 Million Stake in Eli Lilly and Company $LLY - MarketBeat
American Trust Buys 3,644 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) Expands Mounjaro Use to Younger Patients in Euro - GuruFocus
Eli Lilly’s Retatrutide Study: A New Hope for CKD Treatment? - TipRanks
Eli Lilly’s New Study on Obesity Drug LY4167586: What Investors Need to Know - TipRanks
Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment - TipRanks
Eli Lilly Completes Phase 1 Study of Eloralintide for Obesity in China - TipRanks
Eli Lilly Weight Loss Drug Shows Impressive Results in Phase 3 Trial - InsideHook
2 Predictions for Novo Nordisk in 2026 - The Motley Fool
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025) - ts2.tech
Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus - MSN
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025) - ts2.tech
Liontrust Investment Partners LLP Grows Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Rexford Capital Inc. Purchases Shares of 1,488 Eli Lilly and Company $LLY - MarketBeat
Public Sector Pension Investment Board Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Castleark Management LLC Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Brick & Kyle Associates Purchases 1,700 Shares of Eli Lilly and Company $LLY - MarketBeat
Advisory Services Network LLC Buys 1,351 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - MSN
Eli Lilly’s Stock Sets a New Industry Standard - AD HOC NEWS
Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far? - simplywall.st
Eli Lilly and Company $LLY Shares Sold by Bellevue Group AG - MarketBeat
Eli Lilly: The Right Long-Term Strategy - Seeking Alpha
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
1.22%
0.04%
大文字化:
|
ボリューム (24 時間):